Abhishek Jain: No, I think glad that you asked this question, Yi Chen, because this has been one of our key focus areas and where we have been trying to limit the legal expenses. Happy to report that if you look at our G&A expenses for the fourth quarter, it has come down by roughly $4.5 million. And I know that the team has been very focus in trying to figure out as to how to bring those expenses down, be it through like being more effective and efficient in some of the cases that we need to do. And to be honest, some of the legal cases that we have been kind of into they have started to kind of taper off. For example, the SEC investigation has been decided in our favor. On the PBE audit, there have been a lot of claims that have been actually adjudicated in our favor, and now we have a template there that we can use.
So some of the legal spend is kind of coming down, and we are looking for every single opportunity to be able to reduce them. But looking at the fourth quarter G&A, $4.5 million down, primarily driven by the legal spend there. So that stays a priority.
Yi Chen: Thank you.
Operator: Our next question comes from Nathan Kariko with Stephens. Please proceed with your question.
Unidentified Analyst: Hey guys. This is Jacob on for Mason. Thanks for taking the questions. So just maybe a quick on the guide and apologies if this has been touched on and jumped on a little bit late. But I think you said that your 2024 revenue guidance assumes low-to-single digit testing service revenue growth. Just wondering if maybe you could break that down a little bit further in terms of growth between different organ times, kidney, heart, lung, and are you baking in any ASP increases on there, that would be upside due to commercial wins or anything during the year?
Abhishek Jain: No, sure. So on the testing services side, yes, we are expecting a low to mid-single digit revenue growth. And one of the important pieces here is that I’m baking this in on a fourth quarter revenue base for the testing services revenue. So just from the example standpoint, if you were to kind of have a testing services revenue on the fourth quarter annualized, you will basically get a lower revenue growth for the next year, because you are not taking it for the full-year. But from the assumption standpoint, what I’m assuming is that testing services volume growth would be very similar to the transplant volume growth that we are seeing, which is mid-single digits. So that’s the first part of the play. And then the second piece on the ASP, I’m kind of expecting about 2% to 4% headwind and there could be different scenarios on the ASP.
But I’m not expecting ASP headwinds to be similar to what we had seen in 2022 based on our experience in the last few quarters. And based on all the collection efforts and we are seeing efforts where we have been collecting a lot more cash. So limited headwinds for the ASPs, but the transplant volume growth of mid-single digit, driving the testing services volume growth in mid-single digit, lower by ASP headwind a little bit, that gives us a low-to-mid single digit growth for the testing services revenue, if that makes sense.
Unidentified Analyst: Okay. Got it. Thank you. That’s super helpful. And just maybe one follow-up here on AlloMap Kidney and again, sorry, if this has already been touched on. But just wondering what your expectations are around when you could get a CMS decision on coverage for that test?
Alexander Johnson: Ongoing process as far as seeking coverage. And so we don’t have any specific expectation we work to get it as soon as we can.
Unidentified Analyst: Okay. Got it. Thanks guys. Appreciate it.
Operator: We have reached the end of our question-and-answer session. This concludes today’s conference. Thank you for your participation. You may disconnect your lines at this time.
